Marketing-authorisation holder · United States
Hospira Inc.
239 medicines in 2 countries, as authorisation holder and manufacturer.
Loading…
Marketing-authorisation holder · United States
239 medicines in 2 countries, as authorisation holder and manufacturer.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 239
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| A-HYDROCORT100mg base/vial | 1gm base/vial | 250mg base/vial | 500mg base/vial · Injectable | Hydrocortisone | United States | Not marketed | 1978 |
| A-METHAPRED125mg base/vial | 1gm base/vial | 40mg base/vial | 500mg base/vial · Injectable | Methylprednisolone | United States | Not marketed | 1978 |
| ALFENTANIL0.5mg base/ml · Injectable | Alfentanil | United States | Not marketed | 1999 |
| AMIDATE2mg/ml · Injectable | Etomidate | United States | Marketed | 1982 |
| AMIKACIN SULFATE1g(base)/4ml(250mg/ml) | 250mg base/ml | 500mg(base)/ml(250mg/ml) | 50mg base/ml | 62.5mg base/ml · Injectable | Amikacin | United States | Marketed | 1992 |
| AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER500mg base/100ml · Injectable | Amikacin | United States | Not marketed | 1997 |
| AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE5.2% (5.2gm/100ml) · Injectable | Amino acids | United States | Not marketed | 1984 |
| AMINOCAPROIC ACID IN PLASTIC CONTAINER250mg/ml · Injectable | Aminocaproic acid | United States | Marketed | 1987 |
| AMINOPHYLLINE25mg/ml · Injectable | Aminophylline | United States | Marketed | 1981 |
| AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%100mg/100ml | 200mg/100ml · Injectable | Aminophylline | United States | Not marketed | 1983 |
| AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER100mg/100ml | 200mg/100ml | 400mg/100ml | 500mg/100ml · Injectable | Aminophylline | United States | Not marketed | 1984 |
| AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER3.5%; 36.8mg/100ml; 25gm/100ml; 51mg/100ml; 22.4mg/100ml; 261mg/100ml; 205mg/100ml · Injectable | Amino acids, Calcium chloride, Dextrose, Magnesium chloride, Potassium chloride, Potassium phosphate, Dibasic, Sodium chloride | United States | Not marketed | 1988 |
| AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER4.25%; 10gm/100ml; 51mg/100ml; 176.5mg/100ml; 22.4mg/100ml; 104.5mg/100ml; 205mg/100ml · Injectable | Amino acids, Dextrose, Magnesium chloride, Potassium acetate, Potassium chloride, Potassium phosphate, Dibasic, Sodium chloride | United States | Not marketed | 1988 |
| AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER4.25%; 36.8mg/100ml; 20gm/100ml; 51mg/100ml; 22.4mg/100ml; 261mg/100ml; 205mg/100ml · Injectable | Amino acids, Calcium chloride, Dextrose, Magnesium chloride, Potassium chloride, Potassium phosphate, Dibasic, Sodium chloride | United States | Not marketed | 1988 |
| AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER4.25%; 36.8mg/100ml; 25gm/100ml; 51mg/100ml; 22.4mg/100ml; 261mg/100ml; 205mg/100ml · Injectable | Amino acids, Calcium chloride, Dextrose, Magnesium chloride, Potassium chloride, Potassium phosphate, Dibasic, Sodium chloride | United States | Not marketed | 1988 |
| AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER5%; 36.8mg/100ml; 25gm/100ml; 51mg/100ml; 22.4mg/100ml; 261mg/100ml; 205mg/100ml · Injectable | Amino acids, Calcium chloride, Dextrose, Magnesium chloride, Potassium chloride, Potassium phosphate, Dibasic, Sodium chloride | United States | Not marketed | 1988 |
| AMMONIUM CHLORIDE IN PLASTIC CONTAINER5meq/ml · Injectable | Ammonium | United States | Marketed | 1984 |
| AMRINONE LACTATE5mg base/ml · Injectable | Amrinone | United States | Marketed | 1998 |
| ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE4%; 0.017mg base/1.7ml (4% · Injectable | Articaine, Epinephrine | United States | Not marketed | 2010 |
| ATRACURIUM BESYLATE10mg/ml · Injectable | Atracurium | United States | Marketed | 1996 |
| BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER100% · Liquid | Sterile for injection | United States | Marketed | 1982 |
| BORTEZOMIB3.5mg/vial · Injectable | Bortezomib | United States | Marketed | 2022 |
| BORTEZOMIB1mg/vial | 2.5mg/vial · Powder | Bortezomib | United States | Marketed | 2022 |
| BRETYLOL50mg/ml · Injectable | Bretylium tosilate | United States | Not marketed | |
| BUPIVACAINE HYDROCHLORIDE0.25% | 0.5% | 0.75% · Injectable | Bupivacaine | United States | Marketed | 1978 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 170 | 170 | 0 | CompaniesAll medicines |
| Saudi Arabia | 69 | 69 | 0 | CompaniesAll medicines |
Also in the registers of Brazil, Colombia, Malaysia, Singapore
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia, CUM vigentes; source update 2026-09-16; acquired 2026-10-08.
Licence: CC BY-SA 4.0
National Pharmaceutical Regulatory Agency and Ministry of Health Malaysia, KKMNOW Approved Pharmaceutical Products, https://data.moh.gov.my/data-catalogue/pharmaceutical_products; CC BY 4.0; original data as of 2026-09-30 23:59; acquired 2026-10-16T22:34:39.948031+00:00; Prognia preserves original records and projects exact MAL IDs and category/role fields. No government endorsement implied.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0), exact MOH dataset dedication
Saudi Food and Drug Authority (SFDA), foreign human medicine open-data listing, source scope 2023, retrieved 11 October 2026 UTC; exact original file and response modification date retained.
Licence: Exact SFDA open-data section explicitly offers freely usable named human medicine workbooks; factual-data scope only
Contains information from HSA Listing of Registered Therapeutic Products accessed on 8 October 2026 from data.gov.sg, under Singapore Open Data Licence 1.0: https://data.gov.sg/open-data-licence
Licence: Singapore Open Data Licence
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Keep Hospira Inc.’s medicines accurate on Prognia, see how professionals use them and answer what they ask. A 20-minute call, in English.
Book a callOther companies in the same group.
Ranked by their number of medicines.